On July 20, the DOJ announced it had filed criminal charges alleging that 36 defendants in 13 federal districts across the U.S. had improperly collected $1.2 billion for fraudulent telemedicine, cancer genetic and cardiovascular testing, and DME schemes. The DOJ alleged that the schemes involved laboratory owners and operators paying bribes and kickbacks in exchange for patient referrals from medical professionals who worked with fraudulent companies involved in telemedicine and digital medical technology. Schemes related to telemedicine accounted for over $1 billion of the $1.2 billion alleged losses. Separately, CMS’ Center for Program Integrity announced it had taken administrative actions against 52 providers involved in similar schemes.